Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Renal FailureOpen Access

Network pharmacology-based strategy to investigate pharmacological mechanisms of polysaccharide-free Lycium barbarum extract for chronic kidney disease treatment and verification in an animal model

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMeiyou LiuKGKai GaoJCJia Cui

Discussion

Loading...

Member takes

Overview

Network pharmacology reveals ELB's renoprotective effects in chronic kidney disease, suggesting new therapeutic avenues.

Key Points

  • ELB treatment significantly reduced renal damage and serum levels of BUN and SCr in rats with CKD.
  • Chemical analysis identified 188 components in ELB, with 45 meeting screening criteria linked to CKD-related target genes.
  • Network pharmacology analysis highlighted key hub genes including IL-6, VEGFA, and CASP3 as important in the mechanism of action.
  • The findings support the potential of ELB as a novel therapeutic agent for the management of chronic kidney disease.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d6479461dhttps://doi.org/10.1080/0886022x.2025.2539942
View Full Paper
Ask AI
Bookmark
Share